RE: An Example2 Mar 2021 16:11
Scinv , Eli-Lilly had production in progress before EAU, ( you can wade through the EL investor relations press releases and you will find figures there), so we can expect no less from any other Activ-2 candidate IMO. Can you think of any reason why the the FDA would put us on such a high-profile trial without knowing from the BOD that we can deliver on their estimated required numbers? Nor can I. If you are still not convinced, consider Polar Capital who will have done their own due diligence, including scale-up capability, far beyond what is discussed on this BB. Their increasing stake indicates no red flags to me.